Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 7/20 | 0.45 |
| ▸ | BCHE | P06276 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1570768 | 0.67 | PDE3B (1.00) | PDE3BPDE3AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7316421 | 0.66 | PDE3B (0.97) | PDE3BPDE3AMEN1USP2ALDH1A1 | |
| SCHEMBL6738853 | 0.64 | NPC1 (0.40) | PDE3BPDE3AACHEBCHEMEN1 | |
| SCHEMBL18055615 | 0.64 | KMT2A (0.39) | MEN1USP2ALDH1A1KMT2A | |
| SCHEMBL3260790 | 0.64 | PDE3B (0.75) | PDE3BPDE3AACHEBCHEMEN1 | |
| SCHEMBL3838526 | 0.62 | NPC1 (0.45) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL29416837 | 0.62 | ACHE (1.00) | PDE3BPDE3AACHEBCHEMEN1 | |
| SCHEMBL3387188 | 0.62 | ACHE (1.00) | PDE3BPDE3AACHEBCHEMEN1 | |
| SCHEMBL7856734 | 0.61 | PDE3B (0.41) | PDE3BPDE3AACHEBCHEMEN1 | |
| SCHEMBL247665 | 0.61 | ACHE (0.50) | PDE3BPDE3AACHEBCHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023953-A1 | Tricylic mercaptomethyl-substituted 2,3-dihydro-quinazolin-5-ones and 2,3-dihydro-benzo-[1,2,4]-thiadiazin-5,5-dioxides as matrix metalloproteinase (MMP) inhibitors | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-02-05 | — | — | US | claimed |
| EP-1319010-B1 | TRICYCLIC MERCAPTOMETHYL-SUBSTITUTED 2,3-DIHYDRO-QUINAZOLIN-5-ONES AND 2,3-DIHYDRO-BENZO-[1,2,4]-THIADIAZIN-5,5-DIOXIDES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS | IBFB GMBH PRIVATES INST FUER B (DE) | 2003-12-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023953-A1 | Tricylic mercaptomethyl-substituted 2,3-dihydro-quinazolin-5-ones and 2,3-dihydro-benzo-[1,2,4]-thiadiazin-5,5-dioxides as matrix metalloproteinase (MMP) inhibitors | TPSB2, MMP25, MMP15 | PDE3B 1354/4885PDE3A 1381/4885ACHE 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.